for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Synlogic Inc

SYBX.OQ

Latest Trade

2.58USD

Change

0.02(+0.78%)

Volume

61,411

Today's Range

2.54

 - 

2.62

52 Week Range

2.32

 - 

14.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.56
Open
2.58
Volume
61,411
3M AVG Volume
4.91
Today's High
2.62
Today's Low
2.54
52 Week High
14.56
52 Week Low
2.32
Shares Out (MIL)
31.72
Market Cap (MIL)
81.84
Forward P/E
-1.33
Dividend (Yield %)
--

Next Event

Q3 2019 Synlogic Inc Earnings Release

Latest Developments

More

Synlogic Announces Appointments Of New CMO, Head Of Regulatory Affairs, And CFO Departure

Synlogic Says Selling Stockholder May Offer And Resell Under This Prospectus Of Up To 8.9 Mln Shares Of Co's Common Stock

Synlogic Q2 Loss Per Share $0.45

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Synlogic Inc

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Industry

Biotechnology & Drugs

Contact Info

301 Binney St Ste 402

+1.617.4019975

https://www.synlogictx.com/

Executive Leadership

Michael F. Powell

Chairman of the Board

Aoife M Brennan

President, Chief Executive Officer, Director

Todd Shegog

Chief Financial Officer, Secretary

Paul Miller

Chief Scientific Officer

Jay Stoudemire

Vice President - Preclinical Development, Regulatory and Quality Assurance

Key Stats

2.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-7.350

2017

-6.000

2018

-2.030

2019(E)

-1.934
Price To Earnings (TTM)
--
Price To Sales (TTM)
31.48
Price To Book (MRQ)
0.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.19
LT Debt To Equity (MRQ)
0.04
Return on Investment (TTM)
-26.91
Return on Equity (TTM)
-25.51

Latest News

BRIEF-Synlogic Announces Collaboration To Evaluate Synb1891 In Combination With Pd-L1 In Patients With Advanced Solid Tumors

* SYNLOGIC ANNOUNCES CLINICAL COLLABORATION TO EVALUATE SYNB1891 IN COMBINATION WITH PD-L1 CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS

BRIEF-Synlogic Receives Fast-Track Designation For Synb1618, A Synthetic Biotic Medicine For Treatment Of Phenylketonuria

* SYNLOGIC RECEIVES FAST-TRACK DESIGNATION FOR SYNB1618, A SYNTHETIC BIOTIC™ MEDICINE FOR THE TREATMENT OF PHENYLKETONURIA

BRIEF-Synlogic Doses First Subject In Phase 1/2A Trial Of Synb1618 For Treatment Of Phenylketonuria

* SYNLOGIC DOSES FIRST SUBJECT IN PHASE 1/2A TRIAL OF SYNB1618 FOR TREATMENT OF PHENYLKETONURIA

BRIEF-Hawkes Bay Master Investors (Cayman) L.P. Reports 5.30 Pct Passive Stake In Synlogic As Of April 06, 2018

* HAWKES BAY MASTER INVESTORS (CAYMAN) L.P. REPORTS 5.30 PERCENT PASSIVE STAKE IN SYNLOGIC INC AS OF APRIL 06, 2018 - SEC FILING Source text: (https://bit.ly/2IYd3gd) Further company coverage:

BRIEF-Synlogic Doses First Patient In Phase 1b/2a Trial Of SYNB1020 For Treatment Of Hyperammonemia In Patients With Cirrhosis

* SYNLOGIC DOSES FIRST PATIENT IN PHASE 1B/2A TRIAL OF SYNB1020 FOR TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH CIRRHOSIS Source text for Eikon: Further company coverage:

BRIEF-Synlogic Reports Q4 Loss Per Share Of $0.74

* SYNLOGIC REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Synlogic Announces Pricing Of Public Offering Of Common Stock

* SYNLOGIC ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Synlogic Announces Proposed Public Offering Of Common Stock

* SYNLOGIC ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Synlogic Progresses Clinical And Preclinical Pipeline And Outlines 2018 Catalysts

* SYNLOGIC PROGRESSES CLINICAL AND PRECLINICAL PIPELINE AND OUTLINES 2018 CATALYSTS

BRIEF-Synlogic, Ginkgo Bioworks To Collaborate To Discover New Living Medicines To Treat Neurological And Liver Disorders

* SYNLOGIC INC - CO, ORGANISM COMPANY GINKGO BIOWORKS TO COLLABORATE TO DISCOVER NEW LIVING MEDICINES TO TREAT NEUROLOGICAL AND LIVER DISORDERS Source text for Eikon: Further company coverage:

Biotech firms race to recruit good bugs in war on cancer

Biotech companies are competing to develop medicines using "bugs as drugs" to fight cancer, building on the latest scientific findings that patients with high levels of good gut bacteria are more likely to respond to modern immunotherapy.

BRIEF-Synlogic qtrly loss per share $1.66

* Synlogic reports third quarter 2017 financial results and recent progress

BRIEF-Synlogic says ‍SYNB1020 was safe, well tolerated in subjects

* Synlogic reports positive top-line phase 1 data demonstrating safety and tolerability and proof of mechanism in healthy volunteers for synb1020, a synthetic biotictm medicine for the treatment of hyperammonemia

BRIEF-Synlogic receives orphan drug designation for SYNB1618, medicine for the treatment of Phenylketonuria

* Synlogic receives orphan drug designation for SYNB1618, a Synthetic Biotictm medicine for the treatment of Phenylketonuria Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Synlogic says co entered into sales agreement with Cowen And Company, LLC ​

* Synlogic Inc - on October 13, 2017 co entered into a sales agreement with Cowen And Company, LLC - SEC filing

BRIEF-Synlogic files for mixed shelf of up to $200 million

* Synlogic Inc files for mixed shelf of up to $200 million – SEC Filing Source text: (http://bit.ly/2yikB9E) Further company coverage:

BRIEF-‍OrbiMed Advisors reports 8.08 pct stake in Synlogic Inc - SEC filing

* OrbiMed Advisors LLC reports 8.08 percent stake in Synlogic Inc as of Aug 28 - SEC filing Source text: (http://bit.ly/2wcxQps) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Deerfield Management Co LP reports 5.22 pct passive stake in Synlogic as on Aug 28 - SEC Filing

* Deerfield Management Company, L.P. reports 5.22 percent passive stake in Synlogic Inc as on August 28, 2017 - SEC Filing Source text: [http://bit.ly/2wGJI51] Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up